ERBB2 and breast carcinoma: Currently, ongoing clinical trials (NCT00393783, NCT00436254) are evaluating the safety and immunologic activity of DNA-based vaccines encoding different versions of HER2-derived protein in treating HER2-overexpressing breast cancer.